DK200300014A - Anvendelse af stammer af Parapoxvirus ovis mod organfibroser - Google Patents

Anvendelse af stammer af Parapoxvirus ovis mod organfibroser Download PDF

Info

Publication number
DK200300014A
DK200300014A DK200300014A DKPA200300014A DK200300014A DK 200300014 A DK200300014 A DK 200300014A DK 200300014 A DK200300014 A DK 200300014A DK PA200300014 A DKPA200300014 A DK PA200300014A DK 200300014 A DK200300014 A DK 200300014A
Authority
DK
Denmark
Prior art keywords
parapoxvirus ovis
organ fibrosis
drugs
fibrosis
strains against
Prior art date
Application number
DK200300014A
Other languages
Danish (da)
English (en)
Inventor
Hirth-Dietrich Claudia
Schlapp Tobias
Siegling Angela
Knorr Andreas
Weber Olaf
Theiss Gudrun
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DK200300014A publication Critical patent/DK200300014A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK200300014A 2000-07-11 2003-01-10 Anvendelse af stammer af Parapoxvirus ovis mod organfibroser DK200300014A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (1)

Publication Number Publication Date
DK200300014A true DK200300014A (da) 2003-03-07

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200300014A DK200300014A (da) 2000-07-11 2003-01-10 Anvendelse af stammer af Parapoxvirus ovis mod organfibroser

Country Status (30)

Country Link
US (1) US6632647B2 (lt)
EP (1) EP1303302B1 (lt)
JP (1) JP5106736B2 (lt)
CN (1) CN1452496B (lt)
AR (1) AR028800A1 (lt)
AU (2) AU2001285827B2 (lt)
BG (1) BG107447A (lt)
CA (1) CA2415399C (lt)
CZ (1) CZ200372A3 (lt)
DK (1) DK200300014A (lt)
EE (1) EE200300019A (lt)
FI (1) FI20030038A7 (lt)
GB (1) GB2383752B (lt)
HK (1) HK1054330B (lt)
HR (1) HRP20030097A2 (lt)
HU (1) HU227668B1 (lt)
IL (1) IL153826A0 (lt)
LT (1) LT5064B (lt)
LU (1) LU90996B1 (lt)
LV (1) LV12991B (lt)
MA (1) MA25765A1 (lt)
MX (1) MXPA03000278A (lt)
NO (1) NO20030081D0 (lt)
NZ (1) NZ523535A (lt)
PL (1) PL360839A1 (lt)
RU (1) RU2003104522A (lt)
SE (1) SE0300033L (lt)
SI (1) SI21171A (lt)
SK (1) SK382003A3 (lt)
WO (1) WO2002004019A2 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
AU2002353031A1 (en) 2001-12-07 2003-06-23 Bayer Corporation Use of parapox b2l protein to treat cancer and modify immune responses
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
EP3417866B1 (en) 2016-02-16 2020-12-23 Osaka University Medicinal composition for treating fibrosis
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT885013E (pt) * 1996-04-15 2002-01-30 Anton Mayr Prof Dr Med Vet Dr Utilizacao de indutores de para-imunidade multipotentes baseados em poxvirus ou parapoxvirus atenuados e nao imunogenicos para a fabricacao de medicamentos
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
MXPA03000278A (es) 2004-04-05
HUP0303830A3 (en) 2004-10-28
LT2003008A (lt) 2003-07-25
EE200300019A (et) 2004-10-15
FI20030038A7 (fi) 2003-03-10
LT5064B (lt) 2003-11-25
SE0300033L (sv) 2003-03-10
HUP0303830A2 (hu) 2004-04-28
BG107447A (bg) 2003-09-30
LV12991B (en) 2003-08-20
NZ523535A (en) 2004-12-24
US20020076418A1 (en) 2002-06-20
CA2415399A1 (en) 2003-01-08
GB2383752A (en) 2003-07-09
HK1054330A1 (en) 2003-11-28
SK382003A3 (en) 2003-07-01
WO2002004019A2 (de) 2002-01-17
SI21171A (sl) 2003-10-31
US6632647B2 (en) 2003-10-14
GB0302629D0 (en) 2003-03-12
PL360839A1 (pl) 2004-09-20
HU227668B1 (en) 2011-11-28
AU2001285827B2 (en) 2006-11-30
CN1452496B (zh) 2012-10-10
JP5106736B2 (ja) 2012-12-26
HK1054330B (zh) 2005-07-15
CN1452496A (zh) 2003-10-29
RU2003104522A (ru) 2004-06-27
EP1303302B1 (de) 2009-10-14
EP1303302A2 (de) 2003-04-23
JP2004502741A (ja) 2004-01-29
SE0300033D0 (sv) 2003-01-10
LU90996B1 (en) 2003-01-08
IL153826A0 (en) 2003-07-31
WO2002004019A3 (de) 2002-08-01
MA25765A1 (fr) 2003-04-01
HRP20030097A2 (en) 2005-02-28
GB2383752B (en) 2004-11-24
NO20030081L (no) 2003-01-08
AR028800A1 (es) 2003-05-21
CA2415399C (en) 2011-11-08
NO20030081D0 (no) 2003-01-08
CZ200372A3 (cs) 2003-05-14
AU8582701A (en) 2002-01-21

Similar Documents

Publication Publication Date Title
Isaacs et al. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus
Smith et al. Vaccinia virus immune evasion
Bera et al. Zoonotic cases of camelpox infection in India
Verardi et al. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity
Traboulsi et al. The flavonoid isoliquiritigenin reduces lung inflammation and mouse morbidity during influenza virus infection
GB2375113A (en) Virus strains
IL204539A (en) Foxvirus virus containing defective genes and a losing gene
FI963717A7 (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
WO2003078592A3 (en) Method for the purification, production and formulation of oncolytic adenoviruses
KR970701062A (ko) 폭스비루스(poxvirus) 성분의 조합에 기초한 파라뮤니티(paramunity) 유발인자(inducer), 그의 제조방법 및 그의 약제에의 이용
DK200300014A (da) Anvendelse af stammer af Parapoxvirus ovis mod organfibroser
DK200300015A (da) Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer
Criscuolo et al. Smallpox vaccination‐elicited antibodies cross‐neutralize 2022‐Monkeypox virus Clade II
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
Goyal et al. Buffalo pox outbreak with atypical features: a word of caution and need for early intervention!
CA2247388A1 (en) Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
Altmann et al. Antiviral activity of the EB peptide against zoonotic poxviruses
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
Ciborowski et al. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease
Kuo et al. Water extract of Glycyrrhiza uralensis inhibited enterovirus 71 in a human foreskin fibroblast cell line
CN102349995A (zh) 一种广谱抗病毒的药物及其制备方法和应用
PL372091A1 (pl) Ekspresja genów w zmodyfikowanym wirusie krowianki Ankara uzyskana w wyniku zastosowania promotora ATI wirusa ospy krów
Boon et al. The hypervariable immunodominant NP418-426 epitope from the influenza A virus nucleoprotein is recognized by cytotoxic T lymphocytes with high functional avidity
WO2001044280A3 (en) Methods and compositions for the manufacture of replication incompetent adenovirus
Goel et al. COVID-19 Evolution and Alternative Medicine-A Review.

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment